STOCK TITAN

Moolec Science SA (MLEC) Stock Price, News & Analysis

MLEC NASDAQ
Published by Stock Titan Data refreshed

Price Move History

Daily moves over 5%
109 251 sessions, October 31, 2025 to November 2, 2026
Largest daily move
+118.1% close of January 15, 2026
1-year change
-91.2% closing prices, October 31, 2025 to November 2, 2026
1-month change
-82.1% closing prices, October 2, 2026 to November 2, 2026

Company Description

Moolec Science SA (NASDAQ: MLEC) is a science-based food ingredient and life sciences company that focuses on producing animal proteins, nutritional oils, and other functional ingredients in plants and microbes. According to the company’s public statements, Moolec engineers plants and microbes to unlock scalable protein solutions for the global food system, integrating Molecular Farming with precision fermentation to combine the cost efficiency of crops with the functionality and nutrition of animal proteins. Its shares trade on the Nasdaq Capital Market under the ticker symbol MLEC.

Business focus and technology platforms

Moolec describes itself as an innovation-driven company that uses plant engineering and microbial technologies to create ingredients for the food and agriculture value chain. By integrating Molecular Farming and precision fermentation, the company aims to generate sustainable and commercially viable ingredients that can be produced at scale. Public disclosures state that Moolec’s diversified pipeline includes alternative proteins, bioactive compounds, nutritional oils, and biological inputs for regenerative agriculture.

The company reports that it has a significant intellectual property position, with more than 118 granted and pending patents across multiple technology platforms. This portfolio is intended to protect its Molecular Farming innovations, precision fermentation developments, and related ingredient technologies.

Molecular Farming and plant-based ingredient programs

Moolec’s ingredient programs include plant-based systems designed to express animal proteins and specialty lipids directly in crops. The company has disclosed a pipeline that historically included products such as TSP Valorasoy (a soy protein product), Glaso (a safflower oil with high levels of gamma-linolenic acid), SPC2 (a plant-based chymosin), and YEEA1 (an extract derived from a novel yeast biomass). In more recent communications, Moolec has emphasized its GLASO safflower platform and Piggy Sooy™ technology as key Molecular Farming assets.

The GLASO safflower platform is described as a proprietary crop enriched in gamma-linolenic acid (GLA), a specialty oil with nutritional and industrial applications. Moolec has reported regulatory approval in Argentina for its safflower GLASO technology for feed and food use, enabling expansion of this crop and supporting counter-season supply strategies. The company has also highlighted expansion of U.S. acreage dedicated to GLASO production to support revenue-generating activities and to build commercial inventory for customers in sectors such as pet food and human nutrition.

Piggy Sooy™ is described as a soybean plant engineered to express high levels of porcine hemeproteins in its seeds. Moolec has announced that it received a Notice of Allowance from the United States Patent and Trademark Office for this technology, covering the plants and seeds, the method used to develop them, and food compositions derived from them. The company reports that initial field trials demonstrated promising production yield and high animal protein content in the soluble protein fraction, and that U.S. regulatory authorities determined Piggy Sooy™ is not subject to certain plant pest regulations, which Moolec views as a milestone toward commercialization.

Precision fermentation and expanded life sciences platform

Through a strategic business combination with Bioceres Group Limited, Gentle Technologies Corp, and Nutrecon LLC, Moolec has described an expanded platform that spans food ingredients, ag-biologicals, precision fermentation, biomaterials, and R&D services. Following the closing of this business combination, Moolec stated that it would continue operating under the Moolec Science name as the parent company of an enlarged enterprise focused on sustainable solutions from molecule to ingredient.

As part of this transaction and subsequent integration, Moolec has highlighted the incorporation of Mycofood™ as a dedicated platform for fungal-based alternative proteins via precision fermentation, with applications under evaluation by food industry partners in North America and Europe. The company positions this fungal protein platform as complementary to its Molecular Farming programs, broadening its protein technology portfolio.

Ag-biologicals, regenerative agriculture, and biomaterials

In connection with the business combination, Moolec has indicated that it will offer upstream technologies for regenerative agriculture through brands associated with Bioceres Group, including biological inputs and climate-smart seeds under the Rizobacter®, ProFarm®, and HB4® brands. The company also references activities in emerging technologies for grain and biomass transformation, particularly in the biomaterials space, and new concepts in farm equipment that integrate material science, electric mobility, and autonomy, developed through subsidiaries of Gentle Tech and Bioceres Group.

Moolec has stated that its pipeline includes biological inputs for regenerative agriculture, aligning its ingredient and technology development with agricultural practices that seek to improve soil health and resource efficiency. These capabilities are supported by R&D and technical infrastructure platforms such as Agrality® and Synbio Powerlabs®, which Moolec describes as providing in-house R&D, contract development and manufacturing (CDMO), and regulatory capabilities to accelerate technology development and regulatory progression.

Operational footprint and markets

According to company disclosures, Moolec has operations spanning the United States, Europe, and South America. Earlier descriptions indicated that the company’s maximum revenues from operations were in Argentina. Subsequent press releases emphasize activities in the United States (including GLASO safflower campaigns and acreage expansion), regulatory approvals and potential counter-season supply strategies in Argentina, and commercial development and partnerships in North America and Europe for its protein and lipid ingredients.

Moolec has reported that it is engaging with organizations in the pet food and human nutrition industries, as well as wellness and performance brands in the nutrition and supplements market, particularly in relation to its GLASO safflower oil platform. The company has also indicated interest in high-concentration GLA softgel applications and access to established softgel distribution channels, positioning GLASO-derived ingredients for use in high-value nutritional markets.

Capital markets, listing status, and share structure

Moolec Science SA is publicly listed on the Nasdaq Capital Market under the symbol MLEC, with publicly traded warrants under the symbol MLECW. The company has disclosed several capital markets and listing-related developments.

Moolec has reported receiving determination letters from Nasdaq related to compliance with listing rules, including the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2), the timely filing of its Annual Report on Form 20-F, and the minimum stockholders’ equity requirement under Nasdaq Listing Rule 5550(b)(1). In each case, the company has publicly stated its intent to appeal or address these matters, including by requesting hearings before a Nasdaq Hearings Panel and by working to complete required filings.

To support compliance with Nasdaq listing standards, the company has implemented share structure changes. Moolec announced a reverse stock split (share consolidation) at a ratio of one-for-ten, reducing the number of issued and outstanding ordinary shares while maintaining the same par value per share. Later, Moolec’s shareholders approved, and the board implemented, a further share consolidation at a ratio of 15-for-1, consolidating every 15 ordinary shares of par value US$0.10 into one ordinary share of par value US$1.50. The company has stated that these consolidations do not affect its business or operations but are intended, among other purposes, to help regain compliance with Nasdaq’s minimum bid price requirement.

Moolec has also disclosed that it received a staff determination letter regarding the minimum stockholders’ equity requirement and that management expects to regain compliance through recognition of an accounting gain related to the derecognition of certain subsidiaries following bankruptcy proceedings. The company has indicated that this derecognition process is underway.

Corporate structure and jurisdiction

Moolec Science SA is described in SEC filings as a public limited liability company incorporated under the laws of the Cayman Islands, with principal executive offices in Grand Cayman, Cayman Islands. The company files reports with the U.S. Securities and Exchange Commission as a foreign private issuer, including Form 20-F annual reports and Form 6-K current reports.

Intellectual property and regulatory milestones

The company emphasizes its intellectual property portfolio, stating that it holds more than 118 granted and pending patents across multiple technology platforms. These include patents related to Molecular Farming innovations such as Piggy Sooy™ and GLASO™, as well as precision fermentation and related life sciences technologies.

Regulatory milestones disclosed by Moolec include the U.S. regulatory determination that Piggy Sooy™ does not present a plant pest risk difference from conventional soybeans under specific regulations, and feed and food approval in Argentina for its safflower GLASO technology. These regulatory decisions are presented by the company as important steps toward commercialization and expansion of its ingredient platforms.

Position within the food-tech and life sciences landscape

Through its combination of Molecular Farming, precision fermentation, ag-biologicals, and biomaterials initiatives, Moolec positions itself at the intersection of biotechnology and food production. Public communications describe the company as focusing on sustainable life sciences and food-tech innovation, with a seed-to-ingredient approach designed to transform aspects of food production and agricultural inputs.

Moolec’s activities span ingredient innovation (such as Piggy Sooy™, GLASO™, and Mycofood™), biological inputs and climate-smart seeds, and technical services through R&D and CDMO platforms. The company presents these elements as part of an integrated life science platform intended to support sustainable growth and long-term value creation within the food and agriculture sectors.

Stock Performance

$0.8500
No recent trading
Last close: November 2, 2026
-91.2%
1 year to November 2, 2026

Moolec Science SA (MLEC) closed at $0.8500 on November 2, 2026. In the 12 months to November 2, 2026, the price lost 91.2%.

See what a $1,000 investment in MLEC was worth at its last close

MLEC Metrics & Rankings

Price returns through November 2, 2026. Month and year figures include the first trading day. Ranking links may use different dates.

Latest News

Moolec Science SA has 10 recent news articles. Of the recent coverage, 5 articles coincided with positive price movement and 4 with negative movement. View all MLEC news →

Financial Highlights

Moolec Science SA generated $5.6M in revenue in FY2024, retaining a 8.4% gross margin, operating income reached -$9.0M, and net income was -$7.3M. Diluted earnings per share stood at -$0.19. The company generated -$9.3M in operating cash flow. The current ratio was 1.69, measuring current assets divided by current liabilities.

$5.6M
Revenue (FY2024)
-$7.3M
Net Income (FY2024)
-$9.3M
Operating Cash Flow

Upcoming Events

YEAR
2027
2027 Operations

2027 commercial expansion

Planned 2027 GLASO1 commercial expansion to scale safflower production; expected large cultivation in American Falls, Idaho.

Moolec Science SA has 1 upcoming scheduled event. The next event, "2027 commercial expansion", is expected in 2027. Investors can track these dates to stay informed about potential catalysts that may affect the MLEC stock price.

Short Interest History

Last 12 Months

Short interest in Moolec Science SA (MLEC) currently stands at 6.3 thousand shares, up 12.7% from the previous reporting period, representing 1.1% of the float. Since the latest stock split, short interest has decreased by 73.6%, measured from January 2026.

Days to Cover History

Last 12 Months

Days to cover for Moolec Science SA (MLEC) currently stands at 1.0 days. The ratio is the reported short interest divided by the average daily trading volume. Across the settlements charted above, it has ranged from 1.0 to 2.1 days.

MLEC Company Profile & Sector Positioning

Moolec Science SA (MLEC) operates in the Biotechnology industry within the broader Healthcare sector and is listed on the NASDAQ.

Investors comparing MLEC often look at related companies in the same sector, including Cibus, Inc. (CBUS), Dyadic International, Inc. (DYAI), Impact BioMedical, Inc. (IBO), Pluri Inc. (PLUR), and Enveric Biosciences, Inc. (ENVB). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate MLEC's relative position within its industry.

Frequently Asked Questions

Moolec Science SA (MLEC) has no recent trading. Its last close was $0.8500 on November 2, 2026.

The FY2024 revenue of Moolec Science SA (MLEC) is $5.6M, from its most recent completed fiscal year.

The FY2024 net income of Moolec Science SA (MLEC) is -$7.3M, from its most recent completed fiscal year.

The diluted earnings per share (EPS) of Moolec Science SA (MLEC) is -$0.19 for FY2024, its most recent completed fiscal year. Learn more about EPS .

The operating cash flow of Moolec Science SA (MLEC) is -$9.3M for FY2024, its most recent completed fiscal year. Learn about cash flow.

The gross profit margin of Moolec Science SA (MLEC) is 8.4% for FY2024, its most recent completed fiscal year. Learn about gross margins.

The current ratio of Moolec Science SA (MLEC), current assets divided by current liabilities, was 1.69 at the end of FY2024, its most recent completed fiscal year. Learn about liquidity ratios.

The gross profit of Moolec Science SA (MLEC) is $473K for FY2024, its most recent completed fiscal year.

The operating income of Moolec Science SA (MLEC) is -$9.0M for FY2024, its most recent completed fiscal year. Learn about operating income.